BR112013024965A2 - composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto - Google Patents

composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto

Info

Publication number
BR112013024965A2
BR112013024965A2 BR112013024965A BR112013024965A BR112013024965A2 BR 112013024965 A2 BR112013024965 A2 BR 112013024965A2 BR 112013024965 A BR112013024965 A BR 112013024965A BR 112013024965 A BR112013024965 A BR 112013024965A BR 112013024965 A2 BR112013024965 A2 BR 112013024965A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
viral infections
treating viral
Prior art date
Application number
BR112013024965A
Other languages
English (en)
Inventor
Wilkinson Barrie
Alan Gregory Matthew
James Moss Steven
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of BR112013024965A2 publication Critical patent/BR112013024965A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto são fornecidos, inter alia, compostos da fórmula (i): para o uso no tratamento de infecção viral ou como um imunossupressor.
BR112013024965A 2011-03-29 2012-03-29 composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto BR112013024965A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production
PCT/GB2012/050707 WO2012131377A1 (en) 2011-03-29 2012-03-29 Macrocyclic compounds and methods for their production

Publications (1)

Publication Number Publication Date
BR112013024965A2 true BR112013024965A2 (pt) 2017-04-18

Family

ID=46001313

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013024965A BR112013024965A2 (pt) 2011-03-29 2012-03-29 composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto
BR112013024974A BR112013024974A2 (pt) 2011-03-29 2012-03-29 composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013024974A BR112013024974A2 (pt) 2011-03-29 2012-03-29 composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto

Country Status (29)

Country Link
US (2) US9139613B2 (pt)
EP (2) EP2691413B1 (pt)
JP (2) JP6118793B2 (pt)
KR (2) KR101868084B1 (pt)
CN (3) CN107417766A (pt)
AR (1) AR085724A1 (pt)
AU (2) AU2012235880B2 (pt)
BR (2) BR112013024965A2 (pt)
CA (2) CA2830827C (pt)
CL (2) CL2013002740A1 (pt)
CY (2) CY1116318T1 (pt)
DK (2) DK2691412T3 (pt)
EA (2) EA023848B1 (pt)
ES (2) ES2533437T3 (pt)
HK (2) HK1189236A1 (pt)
HR (2) HRP20150187T1 (pt)
IL (2) IL228509B (pt)
JO (1) JO3063B1 (pt)
MX (2) MX345351B (pt)
MY (2) MY170637A (pt)
PL (2) PL2691412T3 (pt)
PT (2) PT2691413E (pt)
RS (2) RS53964B1 (pt)
SG (2) SG193568A1 (pt)
SI (2) SI2691412T1 (pt)
TW (1) TWI525098B (pt)
UY (1) UY33993A (pt)
WO (2) WO2012131371A1 (pt)
ZA (2) ZA201307149B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541853T3 (es) 2010-02-09 2015-07-27 Neurovive Pharmaceutical Ab Compuestos basados en sangliferina
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
CA3043131A1 (en) 2016-11-18 2018-05-24 Neurovive Pharmaceutical Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
AU2006259348B2 (en) * 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
CA2674296C (en) 2007-01-04 2015-11-24 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
US8962329B2 (en) 2008-09-24 2015-02-24 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Gene cluster
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
ES2541853T3 (es) * 2010-02-09 2015-07-27 Neurovive Pharmaceutical Ab Compuestos basados en sangliferina
CN107090476B (zh) * 2010-12-20 2021-09-24 爱博利瓦有限公司 Sanglifehrin衍生物及其制备方法
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
US9090657B2 (en) 2015-07-28
CA2830831C (en) 2020-03-10
AU2012235961B2 (en) 2016-09-01
MX2013011043A (es) 2014-04-25
CL2013002739A1 (es) 2014-07-11
AU2012235961A1 (en) 2013-10-10
AU2012235880A1 (en) 2013-10-17
HK1189237A1 (en) 2014-05-30
WO2012131377A1 (en) 2012-10-04
IL228509B (en) 2018-02-28
HRP20150187T1 (en) 2015-06-05
EA201391399A1 (ru) 2014-02-28
PT2691413E (pt) 2015-03-25
JP2014510746A (ja) 2014-05-01
RS53963B1 (en) 2015-08-31
PT2691412E (pt) 2015-03-25
PL2691413T3 (pl) 2015-05-29
ES2533438T3 (es) 2015-04-10
KR101868084B1 (ko) 2018-06-18
EP2691412B1 (en) 2014-12-24
ZA201307231B (en) 2015-05-27
MY170637A (en) 2019-08-21
US20140038885A1 (en) 2014-02-06
EP2691413B1 (en) 2014-12-24
CN103619869B (zh) 2015-11-25
EP2691413A1 (en) 2014-02-05
IL228509A0 (en) 2013-12-31
SI2691412T1 (sl) 2015-05-29
CN107417766A (zh) 2017-12-01
KR101911484B1 (ko) 2018-10-24
UY33993A (es) 2012-10-31
CN103635484B (zh) 2017-05-10
BR112013024974A2 (pt) 2016-09-06
TWI525098B (zh) 2016-03-11
AU2012235880B2 (en) 2016-11-17
CY1116318T1 (el) 2017-02-08
DK2691413T3 (en) 2015-04-07
RS53964B1 (en) 2015-08-31
EA023907B1 (ru) 2016-07-29
CN103619869A (zh) 2014-03-05
CA2830827A1 (en) 2012-10-04
MX345352B (es) 2017-01-26
CA2830831A1 (en) 2012-10-04
KR20140071958A (ko) 2014-06-12
WO2012131371A1 (en) 2012-10-04
JO3063B1 (ar) 2017-03-15
MX2013011051A (es) 2014-03-13
HRP20150184T1 (hr) 2015-05-08
US20120251581A1 (en) 2012-10-04
ZA201307149B (en) 2015-04-29
CL2013002740A1 (es) 2014-07-11
JP2014514290A (ja) 2014-06-19
CN103635484A (zh) 2014-03-12
EA201391396A1 (ru) 2014-02-28
CA2830827C (en) 2020-03-10
MX345351B (es) 2017-01-26
IL228508B (en) 2018-01-31
AR085724A1 (es) 2013-10-23
MY170618A (en) 2019-08-21
EA023848B1 (ru) 2016-07-29
KR20140057481A (ko) 2014-05-13
SG193568A1 (en) 2013-11-29
TW201300398A (zh) 2013-01-01
IL228508A0 (en) 2013-12-31
JP6118793B2 (ja) 2017-04-26
SI2691413T1 (sl) 2015-05-29
DK2691412T3 (en) 2015-04-07
SG193569A1 (en) 2013-11-29
EP2691412A1 (en) 2014-02-05
JP6118792B2 (ja) 2017-04-26
US9139613B2 (en) 2015-09-22
ES2533437T3 (es) 2015-04-10
CY1116186T1 (el) 2017-02-08
HK1189236A1 (en) 2014-05-30
PL2691412T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
BR112013024965A2 (pt) composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto
MY173422A (en) Purine derivatives for the treatment of viral infections
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112014030649A2 (pt) inibidores macrocíclicos da flaviviridae vírus
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
EA201590197A1 (ru) Соединения для лечения парамиксовирусных вирусных инфекций
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
BR112013003101A2 (pt) inibidores do vírus da hepatite c
MY167797A (en) Macrocyclic purines for the treatment of viral infections
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MX340190B (es) Compuestos para tratar infecciones por virus sincitial respiratorio.
PH12015501088A1 (en) Dimeric compounds
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
PH12015500185A1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
BR112012019866A2 (pt) composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
BRPI0923324A2 (pt) Composto, uso de um composto, método para inibição da dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente, e, processo para preparar um composto.
PH12015500399A1 (en) Azaindolines

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements